Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO).
Demirci U, Tufan G, Aktas B, Balakan O, Alacacioglu A, Dane F, Engin H, Kaplan MA, Gunaydin Y, Ozdemir NY, Tugba Unek I, Karaca H, Akman T, Sonmez OU, Coskun U, Harputluoglu H, Sevinc A, Tonyali O, Buyukberber S, Benekli M. Demirci U, et al. Among authors: gunaydin y. J Cancer Res Clin Oncol. 2013 May;139(5):829-35. doi: 10.1007/s00432-013-1390-8. Epub 2013 Feb 12. J Cancer Res Clin Oncol. 2013. PMID: 23400732
Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab.
Tonyali O, Coskun U, Sener N, Inanc M, Akman T, Ulas A, Yazilitas D, Bal O, Kucukoner M, Yildirim Ozdemir N, Demirci U, Gunaydin Y, Yildiz R, Karaca H, Umit Unal O, Gumus M, Benekli M, Buyukberber S. Tonyali O, et al. Among authors: gunaydin y. Onkologie. 2013;36(10):554-8. doi: 10.1159/000355156. Epub 2013 Sep 16. Onkologie. 2013. PMID: 24107908
Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab.
Tonyali O, Coskun U, Yuksel S, Inanc M, Bal O, Akman T, Yazilitas D, Ulas A, Kucukoner M, Aksoy A, Demirci U, Uysal M, Tanriverdi O, Gunaydin Y, Sumbul AT, Yildiz R, Karaca H, Oksuzoglu B, Ciltas A, Buyukberber S, Benekli M; Anatolian Society of Medical Oncology (ASMO). Tonyali O, et al. Among authors: gunaydin y. Breast. 2016 Feb;25:22-6. doi: 10.1016/j.breast.2015.11.006. Epub 2015 Dec 20. Breast. 2016. PMID: 26801412
Treatment and prognostic factors in primary peritoneal carcinoma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO).
Unal OU, Oztop I, Yazici O, Ozatli T, Inal A, Günaydın Y, Alici S, Demirci U, Cinkir HY, Aktas B, Aslan K, Uncu D, Yilmaz AU, Oksuzoglu B, Buyukberber S. Unal OU, et al. Among authors: gunaydin y. Oncol Res Treat. 2014;37(6):332-8. doi: 10.1159/000362857. Epub 2014 May 19. Oncol Res Treat. 2014. PMID: 24903764 Clinical Trial.
Biological Subtypes and Distant Relapse Pattern in Breast Cancer Patients After Curative Surgery (Study of Anatolian Society of Medical Oncology).
Kaplan MA, Arslan UY, Işıkdogan A, Dane F, Oksuzoglu B, Inanc M, Akman T, Kucukoner M, Cinkir HY, Rzazade R, Ozkan M, Yilmaz U, Bayoglu IV, Gunaydin Y, Baykara M, Yazilitas D, Cubukcu E, Suner A, Ersoy U, Bilici M, Yazici O, Cayır K, Demirci U, Uysal M. Kaplan MA, et al. Among authors: gunaydin y. Breast Care (Basel). 2016 Aug;11(4):248-252. doi: 10.1159/000448186. Epub 2016 Aug 9. Breast Care (Basel). 2016. PMID: 27721711 Free PMC article.
Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors.
Gumus M, Bilici A, Odabas H, Ustaalioglu BBO, Kandemir N, Demirci U, Cihan S, Bayoglu IV, Ozturk T, Turkmen E, Urakci Z, Seker MM, Gunaydin Y, Selcukbiricik F, Turan N, Sevinc A. Gumus M, et al. Among authors: gunaydin y. World J Urol. 2017 Jul;35(7):1103-1110. doi: 10.1007/s00345-016-1964-6. Epub 2016 Nov 3. World J Urol. 2017. PMID: 27812752
Adult Urological Soft Tissue Sarcomas: A Multicenter Study of the Anatolian Society of Medical Oncology (ASMO).
Unal OU, Oztop I, Menekse S, Urakci Z, Bozkurt O, Ozcelik M, Gunaydin Y, Yasar N, Yazilitas D, Kodaz H, Taskoylu BY, Aksoy A, Demirci U, Araz M, Tonyali O, Sevinc A, Yilmaz AU, Benekli M. Unal OU, et al. Among authors: gunaydin y. Asian Pac J Cancer Prev. 2015;16(11):4777-80. doi: 10.7314/apjcp.2015.16.11.4777. Asian Pac J Cancer Prev. 2015. PMID: 26107239 Free article.
Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen.
Sendur MA, Ozdemir N, Özatlı T, Yazıcı O, Aksoy S, Ekinci AS, Yazılıtaş D, Günaydın Y, Oksuzoglu B, Benekli M, Zengin N. Sendur MA, et al. Among authors: gunaydin y. Med Oncol. 2014 Sep;31(9):153. doi: 10.1007/s12032-014-0153-y. Epub 2014 Aug 7. Med Oncol. 2014. PMID: 25099765
Salvage treatment experience in advanced synovial sarcoma: a multicenter retrospective analysis of the Anatolian society of medical oncology.
Yetisyigit T, Arpaci E, Seber ES, Kucukoner M, Kos FT, Sonmez OU, Alici S, Akman T, Aktas B, Yildiz R, Gunaydin Y, Inanc M, Demirci U, Alkis N, Gumus M. Yetisyigit T, et al. Among authors: gunaydin y. Asian Pac J Cancer Prev. 2013;14(9):5185-8. doi: 10.7314/apjcp.2013.14.9.5185. Asian Pac J Cancer Prev. 2013. PMID: 24175798 Free article.
86 results